Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy.

Sun X, Yang D, Li Y, Shi J, Zhang X, Yi T

Peptides4 Apr 2024Cited by 3 (Europe PMC)

PMID38582303DOI10.1016/j.peptides.2024.171203PepBankPUB-38582303

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

2 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In diet-induced obese mice in a chronic study, cagrilintide alone reduced body weight by 5.7%.
In plain wordsIn mice, cagrilintide alone reduced body weight by 5.7%, less than the combinations tested.
Peptide
Cagrilintide
Outcome
DecreaseBody weight change with cagrilintide alone
Study
mousen: not reported in source
Diet-induced obesity (high-fat diet) mice
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Body weight change
−5.7%
cagrilintide alone
Source sentences
Summary
Notably, in a chronic study involving DIO mice, the combination of bGLP-10 with the amylin analogue cagrilintide led to a more substantial weight loss (-38.4%, P < 0.001) compared to either the semaglutide-cagrilintide combination (-23.0%) or cagrilintide (-5.7%), bGLP-10 (-16.1%), and semaglutide (-10.9%) alone.
Report a problemFND-3858230303
02AnimalAnimal study (in vivo)Efficacy outcome
In diet-induced obesity mice, semaglutide alone reduced body weight by 10.9% in a chronic study, less than the bGLP-10-cagrilintide combination.
In plain wordsIn mice with diet-induced obesity, semaglutide alone lowered body weight by 10.9%, less than a bGLP-10-cagrilintide combination.
Peptide
Semaglutide
Outcome
DecreaseBody weight change in chronic DIO study, semaglutide alone
Study
mousen: not reported in source
Diet-induced obesity (DIO) mice
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
body weight change
−10.9%
semaglutide alone
Source sentences
Summary
Notably, in a chronic study involving DIO mice, the combination of bGLP-10 with the amylin analogue cagrilintide led to a more substantial weight loss (-38.4%, P < 0.001) compared to either the semaglutide-cagrilintide combination (-23.0%) or cagrilintide (-5.7%), bGLP-10 (-16.1%), and semaglutide (-10.9%) alone.
Report a problemFND-3858230306

Studies that did not test the peptide alone5

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03AnimalNot a test of Cagrilintide aloneAnimal study (in vivo)Efficacy outcome
In diet-induced obese mice in a chronic study, bGLP-10 plus cagrilintide reduced body weight more than semaglutide plus cagrilintide or any single drug.
In plain wordsIn mice, bGLP-10 combined with cagrilintide caused more weight loss than semaglutide with cagrilintide or any of the single drugs.
Peptide
Cagrilintide
Outcome
DecreaseBody weight change with bGLP-10 plus cagrilintide
Study
mousen: not reported in source
Diet-induced obesity (high-fat diet) mice
Comparator
Semaglutide plus cagrilintide; cagrilintide, bGLP-10 and semaglutide alone
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight change
−38.4%
bGLP-10 plus cagrilintide
Source sentences
Summary
Notably, in a chronic study involving DIO mice, the combination of bGLP-10 with the amylin analogue cagrilintide led to a more substantial weight loss (-38.4%, P < 0.001) compared to either the semaglutide-cagrilintide combination (-23.0%) or cagrilintide (-5.7%), bGLP-10 (-16.1%), and semaglutide (-10.9%) alone.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-3858230301
04AnimalNot a test of Cagrilintide aloneAnimal study (in vivo)Efficacy outcome
In diet-induced obese mice in a chronic study, semaglutide plus cagrilintide reduced body weight by 23.0%.
In plain wordsIn mice, semaglutide combined with cagrilintide reduced body weight by 23.0%.
Peptide
Cagrilintide
Outcome
DecreaseBody weight change with semaglutide plus cagrilintide
Study
mousen: not reported in source
Diet-induced obesity (high-fat diet) mice
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight change
−23%
semaglutide plus cagrilintide
Source sentences
Summary
Notably, in a chronic study involving DIO mice, the combination of bGLP-10 with the amylin analogue cagrilintide led to a more substantial weight loss (-38.4%, P < 0.001) compared to either the semaglutide-cagrilintide combination (-23.0%) or cagrilintide (-5.7%), bGLP-10 (-16.1%), and semaglutide (-10.9%) alone.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-3858230302
05AnimalNot a test of Cagrilintide aloneAnimal study (in vivo)Efficacy outcome
In diet-induced obese mice, bGLP-10 plus cagrilintide gave better glucose control than semaglutide plus cagrilintide (P < 0.001).
In plain wordsIn mice, bGLP-10 with cagrilintide controlled glucose better than semaglutide with cagrilintide.
Peptide
Cagrilintide
Outcome
IncreaseGlucose control with bGLP-10 plus cagrilintide
Study
mousen: not reported in source
Diet-induced obesity (high-fat diet) mice
Comparator
Semaglutide plus cagrilintide
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Furthermore, the bGLP-10 and cagrilintide combination exhibited superior glucose control and liver lipid management compared to the semaglutide-cagrilintide combination (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Notably, in a chronic study involving DIO mice, the combination of bGLP-10 with the amylin analogue cagrilintide led to a more substantial weight loss (-38.4%, P < 0.001) compared to either the semaglutide-cagrilintide combination (-23.0%) or cagrilintide (-5.7%), bGLP-10 (-16.1%), and semaglutide (-10.9%) alone.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-3858230304
06AnimalNot a test of Cagrilintide aloneAnimal study (in vivo)Efficacy outcome
In diet-induced obese mice, bGLP-10 plus cagrilintide gave better liver lipid management than semaglutide plus cagrilintide (P < 0.001).
In plain wordsIn mice, bGLP-10 with cagrilintide managed liver fat better than semaglutide with cagrilintide.
Peptide
Cagrilintide
Outcome
IncreaseLiver lipid management with bGLP-10 plus cagrilintide
Study
mousen: not reported in source
Diet-induced obesity (high-fat diet) mice
Comparator
Semaglutide plus cagrilintide
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Furthermore, the bGLP-10 and cagrilintide combination exhibited superior glucose control and liver lipid management compared to the semaglutide-cagrilintide combination (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Notably, in a chronic study involving DIO mice, the combination of bGLP-10 with the amylin analogue cagrilintide led to a more substantial weight loss (-38.4%, P < 0.001) compared to either the semaglutide-cagrilintide combination (-23.0%) or cagrilintide (-5.7%), bGLP-10 (-16.1%), and semaglutide (-10.9%) alone.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-3858230305
07AnimalNot a test of Semaglutide aloneAnimal study (in vivo)Efficacy outcome
In diet-induced obesity mice, the semaglutide-cagrilintide combination reduced body weight by 23.0% in a chronic study, less than bGLP-10 plus cagrilintide.
In plain wordsIn mice with diet-induced obesity, a semaglutide and cagrilintide combination lowered body weight by 23.0%, less than a bGLP-10 and cagrilintide combination.
Peptide
Semaglutide
Outcome
DecreaseBody weight change in chronic DIO study, semaglutide plus cagrilintide
Study
mousen: not reported in source
Diet-induced obesity (DIO) mice
Outcome group
Body weight · Metabolic and weight
Measurements
body weight change
−23%
semaglutide-cagrilintide combination
Source sentences
Summary
Notably, in a chronic study involving DIO mice, the combination of bGLP-10 with the amylin analogue cagrilintide led to a more substantial weight loss (-38.4%, P < 0.001) compared to either the semaglutide-cagrilintide combination (-23.0%) or cagrilintide (-5.7%), bGLP-10 (-16.1%), and semaglutide (-10.9%) alone.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3858230307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.